Abstract
The pattern of inhibition of cell proliferation and cytotoxicity in vitro by 1,4-bis(1-naphthyl)-2,3-dinitro-1,3-butadiene (Naph-DNB) was evaluated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and the trypan blue (TB) dye exclusion assays in nine murine and human cell lines of different histologic origin. In our culture conditions Naph-DNB showed a good inhibiting activity against all cell lines tested, with IC50s varying within a narrow micromolar range of concentrations (2.0 ± 0.2–14.3 ± 2.3 μM). In particular, murine P388 (leukemia), human Jurkat (leukemia), A2780, PA-1 (ovarian carcinoma) and Saos-2 (osteosarcoma) cells showed the highest sensitivity to the inhibiting potential of Naph-DNB, while human A549 (non small cell lung cancer, NSCLC), MDA-MB-231 (breast cancer), HGC-27 (gastric cancer) and HCT-8 (colon carcinoma) were the least sensitive cell lines. Moreover, the analysis of cytotoxicity of Naph-DNB evaluated by the TB test showed that this compound was able to kill cells with IC50s ranging from 1.7 to 39.2 μM. The study of the induction of apoptosis was carried out by 4′-6-diamidine-2′-phenylindole (DAPI) staining of segmented nuclei, western blot of p53 protein and TdT-mediated dUTP-biotin nick end labeling (TUNEL) method, while the interaction with DNA was evaluated through the analysis of interstrand cross-link (ISCL) formation.
Our data show that in all cell lines tested Naph-DNB was able to form ISCLs, to upregulate p53 oncosuppressor-protein and to induce apoptosis. Moreover, TUNEL analysis also suggested that Naph-DNB, similarly to other anticancer drugs, was able to block cells in the G 0/G 1 phase of the cell cycle.
In conclusion our data suggest that Naph-DNB may be an effective novel lead molecule for the design of new anticancer compounds.
Similar content being viewed by others
References
Eckhart S: Recent progress in the development of anticancer agents. Curr Med Chem Anti-Canc Agents 2: 419–439, 2002
Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H, Haga N: Molecular targeting therapy of cancer: Drug resistance, apoptosis and survival signals. Cancer Sci 94: 15–21, 2003
Ferrante K, Winograd B, Canetta R: Promising new developments in cancer chemotherapy. Cancer Chemother Pharmacol 43(Suppl): S61–S68, }1999
Dell'Erba C, Mele A, Novi M, Petrillo G, Stagnaro P: Synthetic exploitation of the ring-opening of 3,4-dinitrothiophene. Access to 1,4-disubstituted 2,3-dinitro-1,3-butadienes and 2,3-butanedione dioximes. Tetrahedron 48: 4407–4418, 1992
Bianchi L, Dell'Erba C, Gabellini A, Novi M, Petrillo G, Tavani C: Access to 3-arylmethyl-5-(methylthio)isoxazoles via an initial ring-opening of 2-methylthio-4-nitrothiophene. Tetrahedron 58: 3379–3385, 2002
Hussain RF, Nouri AME, Oliver RTD: A new approach for measurement of cytotoxicity using colorimetric assay. J Immunol Methods 160: 89–96, 1993
Gorczyca W, Gong J, Darzinkyewicz Z: Detection of DNA strand breaks in individual apoptotic cells by the in situterminal-deoxynucleotidyl-transferase and nick translation assays. Cancer Res 53: 1945–1951, 1993
Coluccia M, Boccarelli A, Mariggi`o MA, Cardellicchio N, Caputo P, Intini FP, Natile G: Platinum(II) complexes containing iminoethers: A trans platinum antitumor agent. Chem-Biol Interact 98: 251–266, 1995
Gao X, Fernandez-Vina M, ShumwaW, Stastny P: DNA typing for class II HLA antigens with allele-specific or group-specific amplification. I. Typinf for subsets of HLA-DR4. Hum Immunol 27: 40–50, 1990
Schwartsmann G, Ratain MJ, Cragg GM, Wong JE, Saijo N, Parkinson DR, FujiwaraY, Pazdur R, Newman DJ, Dagher R, Di Leone L: Anticancer drug discovery and development throughout the world. J Clin Oncol 20(Suppl 15): 47S–59S, 2002
Pakin DM: Global cancer statistics in the year 2000. Lancet Oncol 2: 533–543, 2001
Ferlay J, Bray F, Pisani P, Parkin DM: Globocan 2000: Cancer incidence, mortality and prevalence worldwide, version 1.0 (IARC, CancerBase No. 5). IARC Press, Lyon, 2001
Novi M, Ottone M, Dell'Erba C, Barbieri F, Chiavarina B, Maccagno M, Viale M: 1,4-Bis(1-naphthyl)-2,3-dinitro-1,3-butadiene a novel anticancer compound effective against tumor cell lines characterized by different mechanisms of resistance. Oncol Rep, 12: 91–96, 2004
Kerr JFR, Winterford CM, Harmon BV: Apoptosis-its signifi-cance in cancer and cancer therapy. Cancer 73: 2013–2026, 1994
Green AM, Steinmetz ND: Monitoring apoptosis in real time. Cancer J 8: 82–92, 2002
Gadducci A, Cosio S, Muraca S, Genazzani AR: Molecular mechanisms of apoptosis and chemosensitivity to platinum and paclitaxel in ovarian cancer: Biological data and clinical implications. Eur J Gynaecol Oncol 23: 90–396, 2002
Hickman JA: Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 11: 121–139, 1992
Ciccolini J, Fina F, Bezulier K, Giacometti S, Roussel M, Evrard A, Cuq P, Romain S, Martin PM, Aubert C: Transmission of apoptosis in human colorectal tumor cells exposed to capecitabine, Xeloda, is mediated via Fas. Mol Cancer Ther 1: 923–927, 2002
Mazur L, Augustynek A, Deptala A, Halocka HD, Bedner E: Effects of WR-2721 and cyclophosphamide on the cell cycle phase specificity of apoptosis in mouse bone marrow. Anticancer Drug 13: 751–758, 2002
Martinsson P, Liminga G, Nygren P, Larsson R: Characteristics of etoposide-induced apoptotic cell death in the U-937 human lymphoma cell line. Anticancer Drug 12: 699–705, 2001
Meyn RE, Stephens LC, Hunter NR, Milas L: Apoptosis in murine tumors treated with chemotherapy agents. Anticancer Drug 6: 443–450, 1995
Satomi D, Takiguchi N, Koda K, Oda K, Suzuki H, Yasutomi J, Ishikura H, Miyazaki M: Apoptosis and apoptosisassociated gene products related to the response to neoadjuvant chemotherapy for gastric cancer. Int J Oncol 20: 1167–1171, 2002
Mandziuk S, Dudzisz-Sledz M, Rybacka-Chabros B, Zdunek M, Jakubowicz-Klecha A, Korobowicz E, Milanowski J, Wojcierowski J: Expression of p21 and bcl-2 proteins and p53 mRNAin surgically resected preparations of non-small cell lung cancer (stage IIIA) after etoposide and cisplatin chemotherapy. Folia Histochem Cytobiol: 39(Suppl 2), 175–176, 2001
Gonzales VM, Fuertes MA, Alonso C, Perez JM: Is cisplatininduced cell death always produced by apoptosis? Mol Pharmacol 59: 657–663, 2001
Leist M, Single B, Castoldi AF, Kuhnle S, Nicotera P: Intracellular adenosine triphosphate (ATP) concentration: A switch in the decision between apoptosis and necrosis. J Exp Med 185: 1481–1486, 1997
Pérez JM, Montero EI, Gonźalez AM, Alvarez-Valdés A, Alonso C, Navarro-Ranninger C: Apoptosis induction and inhibition of H-ras overexpression by novel trans-[PtCl2 (isopropylamine)( amine')] complexes. J Inorg Biochem 77: 37–42, 1999
Jordan P, Carmo-Fonseca M: Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci 57:1229–1235, 2000
Malinge JM, Giraud-Panis MJ, Leng M: Interstrand cross-links of cisplatin induce striking distortions in DNA. J Inorg Biochem 77: 23–29, 1999
Cotter TG, McCarthy J: Genes and apoptosis. Biochem Soc Transact 22: 591–593, 1994
Yang Q, Shan L, Yoshimura G, Nakamura M, Nakamura Y, Suzuma T, Umemura T, Mori I, Sakurai T, Kakudo K: 5-Aza-2'_-deoxycytidine induces retinoic acid receptor beta 2 demethylation, cell cycle arrest and growth inhibition in breast carcinoma cells. Anticancer Res 22: 2753–2756, 2002
Pommepuy I, Terro F, Petit B, Trimoreau F, Bellet V, Robert S, Hugon J, Labrousse F, Yardin C: Brefeldin A induces apoptosis and cell cycle blockade in glioblastoma cell lines. Oncology 64: 459–467, 2003
Owa T, Yoshino H, Okauchi T, Yoshimatsu K, Ozawa Y, Sugi NH, Nagasu T, Koyanagi N, Kitoh K. Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. J Med Chem 42(19): 3789–3799, 1999
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Viale, M., Mariggiò, M.A., Ottone, M. et al. Preliminary evaluation in vitro of the inhibition of cell proliferation, cytotoxicity and induction of apoptosis by 1,4-bis(1-naphthyl)-2,3-dinitro-1,3-butadiene. Invest New Drugs 22, 359–367 (2004). https://doi.org/10.1023/B:DRUG.0000036678.25436.3d
Issue Date:
DOI: https://doi.org/10.1023/B:DRUG.0000036678.25436.3d